Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma
Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma
复制标题
肝细胞癌患者肝移植中基于西罗莫司的免疫抑制的生存分析。
DOI：
10.1016/j.clinre.2016.03.006
复制
发表时间：
2016-12-01
影响因子：
2.7
通讯作者：
Chen, Gui-hua
中科院分区：
文献类型：
--
作者：
Xu, Shi-lei;Zhang, Ying-cai;Chen, Gui-hua
Aim: To investigate the effect of a sirolimus-based immunosuppressive protocol on tumor recurrence and survival after liver transplantation (LT) in hepatocellular carcinoma (HCC) patients.Methods: We retrospectively analyzed 142 HCC patients who underwent LT in our hospital from January 2006 to January 2012. The patients were divided into the sirolimus (SRL) group (62 cases) and non-sirolimus (control) group (80 cases). Disease-free survival (DFS) and tumorbearing survival after tumor recurrence were compared using the Kaplan-Meier method.Results: No significant difference in DFS was observed between the two groups. Furthermore, DFS showed no significant differences in the subgroups of patients who met the Milan criteria, exceeded the Milan criteria but met the University of California, San Francisco (UCSF) criteria, or exceeded the UCSF criteria between the two groups. In the control group, 21 patients who were administered SRL after tumor recurrence had a median tumor-bearing survival time of 12 months (3-34 months), while 14 patients who did not experience a change in their immunosuppressive protocol after tumor recurrence had a median tumor-bearing survival time of 8 months (6-22 months). There was a significant difference in the tumor-bearing survival time between these patients (P = 0.039).Conclusions: Not all HCC patients benefited from the sirolimus-based immunosuppressive protocol after LT. However, sirolimus may prolong the survival time of patients after tumor recurrence. (C) 2016 Published by Elsevier Masson SAS.
